Staff Profile

Dr. Rabah Ahmed Taha Serya

---

Biography

---

Dr. Rabah Ahmed Taha Serya Personal Information Name Date of Birth Place of Birth Nationality Marital Status Rabah Ahmed Taha Serya 14-10-1974 Cairo Egyptian Single Contact Information Mailing Address Work Address Phone Number E-mail Address 4 Eldewedar Street-HadaekElkobba Cairo-Egypt Faculty of Pharmacy, Ain Shams University, ElwehdaElAfriqyiast., El Abbasyia sq., Cairo-Egypt Mobile, 01222671182 rabah@pharma.asu.edu.eg rabahat2003@yahoo.com Language Skills Arabic (Mother tongue) English (Excellent) Scientific Degrees 1-Bachelor of Pharmaceutical Sciences, Faculty of pharmacy, Cairo University, May 1997. 2-Master Degree in Pharmaceutical Chemistry, Faculty of pharmacy Ain Sham University, August 2004. 3-Degree of Doctor of Philosophy in Pharmaceutical Chemistry, Faculty of pharmacy, Ain Sham University, April 2009. 4- Associate Professor of Pharmaceutical Chemistry 2016-2021. 5- Professor of Pharmaceutical Chemistry 2021- Now. Professional experience 1- Demonstrator Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, November, 1997 – February, 2004. 2-Assistant Lecturer Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, September , 2004 -October, 2008. 3-Tutorial Lecturer Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, September, 2007. 4-Lecturer Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, Apri, 2009-present. 5- Associate Professor of Pharmaceutical Chemistry 2016-2021 . 6- Acting Head of the Department of Pharmaceutical Chemistry – Ain Shams University 2017-2023 7- Professor of Pharmaceutical Chemistry 2021- Now. 8- Head of the Department of Pharmaceutical Chemistry – Ain Shams University 2024- Now Member of the Department of Pharmaceutical Chemistry Council – Faculty of Pharmacy – Ain Shams University ( 2009 – till now); Member of the undergraduate students’ affairs board – Faculty of Pharmacy – Ain Shams University ( 2016 – till Now); Member of undergraduate examination control committee – Faculty of Pharmacy – Ain Shams University (2009 – 2016); Member of the Faculty Council - Faculty of Pharmacy -Ain Shams University ( 2016 – Now), Theses Completed Master Thesis Synthesis of certain imidazo[5,1-b]quinazoline derivatives having potential biological activity. Ph.D. Thesis Computer based drug design and Synthesis of arylpiperazine derivatives linked to different heterocycles having anti-hypertensive activity. Teaching Experience  Practical Course of Organic Chemistry: synthesis and identification of organic compounds (IR, NMR spectroscopy, Mass spectrometry, Elemental Analysis). .  Practical Course of Pharmaceutical Chemistry: Quantitative and qualitative analysis of drugs and pharmaceutical preparations, HPLC, instrumental analysis.  Practical Course of Computer-Aided Drug design and molecular modeling: Catalyst® and Cerius® software packages and their applications in the process of drug design and discovery (including HipHop, HypoGen, C2.QSAR+, C2.Ludi).  Theoretical Course of Organic Chemistry Basic science of organic chemistry ( org. 1, org. 2, org. 3).  Theoretical Course of Pharmaceutical Chemistry.  Theoretical Course of drug design and molecular modeling.  Lectured advanced organic chemistry, drug design and pharmaceutical chemistry for postgraduate pharmacy students at Ain Shams University.  Examiner of organic and pharmaceutical chemistry at Ain Shams University. Training Courses 1-Starting from 2009 attended six courses for the development of capabilities of Ain Shams University staff members and leadership personnel. 2-Sharing in Lectures and Practical Training for Students and Staff Members in Computer- Aided Drug Design work shops which held in Faculty of Pharmacy, Ain Shams University in April 2003 and 2004. Computer Skills  Completing International Computer Driving License course, organized by Ain Shams University.  Familiar with Microsoft Windows® operating system basic functions (up to XP Version).  Familiar with Microsoft Office® Software Package, including Word, Excel and Power Point (up to XP Version).  Completion of one month course in UNIX operating system, basic functions. Computer Skills in Field of Specialization ▪ Long experience with pharmacophore design and implementation using Catalyst® modules, Accelrys Corporation, San Diego, including: o Molecule drawing, editing, energy minimization o Generation of conformational models o Manual hypothesis generation o HipHop common feature hypothesis generation o HypoGen automatic hypothesis generation o Database search, and prioritization of hits o Prediction of activity of new molecules using Compare/Fit module Cerius2® modules, AccelrysCorporation, San Diego, and their application in drug design and discovery, including the following modules: o C2.Ludi: De novo ligand design o C2.QSAR: design and implementation of QSAR models and their use in prediction of biological activity o C2.LigandFit: docking of ligands onto their macromolecular targets, scoring the docked solutions and use of such data in guiding the drug design process o ADME prediction ▪ Accelrys Discovery Studio 2.5 Docking programs ( Molsoft ICB) Ain Shams University o MOE o Discovery Studio 2.5 ▪ Long experience withChemOffice Suite, including, ChemDraw, Chem3D and ChemFinder Other Skills and Experiences  TOEFL (national), Score: 667 1998 Center of social services/Ain Shams university  TOEFL (international), Score: 657 Amid East- Eldokki  Operation of FT-IR Instrument, Model PerkilnElmer  Operation of GC-Mass Instrument Activities in the Field of Quality Assurance Management 1-Attended workshops and training courses in the quality assurance field for example: -Quality management center- Ain -Shams University. - "Peer Reviewers - Faculty of pharmacy – Ain -Shams University. - "How to prepare study curricula description and designing, writing quality projects", at the Faculty of Pharmacy- Ain Shams University. 2- Member of Quality assurance team since 2009-present. Supervision of Master and PhD theses 1- Supervised 18 Master Theses. 2- Supervised 16 PhD Theses. SPECIAL INTERESTS IN RESEARCH 1) Molecular Modeling and computer based design of new chemical entities and perform VIRTUAL SCREENING of the designed molecules on their specified 3D targets (Enzymes or Receptors) by applying compare fit or docking molecular modeling modules. This technique could help in predicting and explaining the biologically active HIT molecules. 2) Synthetic Organic and Pharmaceutical Chemistry, to construct and build the active hit designed molecules through retro- synthetic approaches. The synthesized molecules involved various potentially active heterocyclic rings. Also, the synthetic strategy involved the incorporation of various side chains having specific pharmacophoric properties to conserve a specified binding affinity to the drug targets and hence increase the potency of the designed new chemical entities. 3) Biological Evaluation of the synthesized hit molecules either in vitro or in vivo, by establishing a cooperation with other disciplines like pharmacology, virology, ... etc, or other research team works. Publication 1- Ismail MA, Aboul-Enein MN, Abouzid KA, Serya RA. Ligand design and synthesis of new imidazo[5,1-b]quinazoline derivatives as alpha1-adrenoceptor agonists and antagonists. Bioorg Med Chem. 2006 Feb 15;14(4):898-910. 2- Elsayed MS, El-Araby ME, Serya RA, Abouzid KA. Synthesis of New Chemical Scaffolds as VEGFR-2 Kinase Inhibitors, Arzneimittelforschung.( 2012); 62(12):554-60 3--Elsayed MS, El-Araby ME, Serya RA, El-Khatib AH, Linscheid MW, Abouzid KA. Structure-based design and synthesis of novel pseudosaccharine derivatives as antiproliferative agents and kinase inhibitors. Eur J Med Chem. 2013 Mar;61:122-31. 4- Sadek MM, Serrya RA, Kafafy AH, Ahmed M, Wang F, Abouzid KA. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents. J Enzyme Inhib Med Chem. 2014 Apr;29(2):215-22. doi: 10.3109/14756366.2013.765417. 5- Ahmed M, Sadek MM, Serrya RA, Kafafy AH, Abouzid KA, Wang F. Assessment of new anti-HER2 ligands using combined docking, QM/MM scoring and MD simulation. J Mol Graph Model. 2013 Mar;40:91-8. doi: 10.1016/j.jmgm.2012.12.001. 6-Abou El-Ella DA, Hussein MM, Serya RA, Abdel Naby RM, Al-Abd AM, Saleh DO, El-Eraky WI, Abouzid KA. Molecular design and synthesis of 1,4-disubstituted piperazines as α(1)-adrenergic receptor blockers. Bioorg Chem. 2014 Jun;54:21-30. doi: 10.1016/j.bioorg.2014.03.005. 7- Abdel-Atty MM, Farag NA, Kassab SE, Serya RA, Abouzid KA. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents. Bioorg Chem. 2014 Dec;57:65-82. doi: 10.1016/j.bioorg.2014.08.006. 8-Nermin S. Abdou, Rabah A. T. Serya, Ahmed Esmat, Mai F. Tolba, Nasser S. M. Ismaila and Khaled A. M. Abouzid. Synthesis and in vitro antiproliferative activity of novel pyrazolo[3,4-d]pyrimidine derivatives Med. Chem. Commun., 2015,6, 1518-1534 DOI: 10.1039/C5MD00127G 9-Dokla EM, Fang CS, Lai PT, Kulp SK, Serya RA, Ismail NS, Abouzid KA, Chen CS. Development of Potent Adenosine Monophosphate Activated Protein Kinase (AMPK) Activators. 1. ChemMedChem. 2015 Sep 9. 2. doi: 10.1002/cmdc.201500371. 3. 10-Nevine M.Y. Elsayed, Dalal A. Abou El Ella, Rabah A.T. Serya, Khaled A.M. Abouzid, Targeting apoptotic machinery as approach for anticancer therapy: Smac mimetics as anticancer agents. 4. Future Journal of Pharmaceutical Sciences. Volume 1, Issue 1, June 2015, Pages 16–21. doi:10.1016/j.fjps.2015.05.005 5. 6. 11-Thieno[2,3-d]pyrimidine based derivatives as kinase inhibitors and anticancer agents 7. Eman Z. Elrazaz, Rabah A.T. Serya, Nasser S.M. Ismail, Dalal A. Abou El Ella, Khaled A.M. Abouzid, 8. Future Journal of Pharmaceutical Sciences Volume 1, Issue 2, December 2015, Pages 33-41 9. 10. 12-Furo[2,3-d]pyrimidine based derivatives as kinase inhibitors and anticancer agents, 11. Marwa A. Aziz, Rabah A.T. Serya, Deena S. Lasheen, Khaled A.M. Abouzid, 12. Future Journal of Pharmaceutical Sciences, , Volume 2, Issue 1, June 2016, Pages 1-8 13-Pyrazolo[3,4-d]pyrimidine based scaffold derivatives targeting kinases as anticancer agents 1. Nasser S. M. Ismail Eslam M. H. Ali, Diaa A. Ibrahim, Rabah A. T. Serya Dalal A. Abou El Ella 2. Future Journal of Pharmaceutical Sciences, Volume 2, Issue 1 June 2016, Pages 20-30 3. 14-Anti-acetylcholinesterase activity of essential oils and their major constituents from four Ocimum species. Farag MA, Ezzat SM, Salama MM, Tadros MG, Serya RA. Z Naturforsch C. 2016 Nov 1;71(11-12):393-402 15-Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents. Aziz MA, Serya RA, Lasheen DS, Abdel-Aziz AK, Esmat A, Mansour AM, Singab AN, Abouzid KA. Sci Rep. 2016 Apr 15;6:24460 16-Design, synthesis and biological evaluation of indazole–pyrimidine based derivatives as anticancer agents with anti-angiogenic and antiproliferative activities Nevine M. Y. Elsayed, Dalal A. Abou El Ella, Rabah A. T. Serya, Mai F. Tolba, Raed Shalaby and Khaled A. M. Abouzid Med. Chem. Commun., 2016,7, 881-899 17-How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors. Milik SN, Lasheen DS, Serya RAT, Abouzid KAM. Eur J Med Chem. 2017 Jul 18. pii: S0223-5234(17)30545-7. 18-Synthesis, ADMET Properties, and Biological Evaluation of Benzothiazole Compounds Targeting Chemokine Receptor 2 (CXCR2). Mehanna WE, Lu T, Debnath B, Lasheen DS, Serya RAT, Abouzid KA, Neamati N. ChemMedChem. 2017 Jul 6;12(13):1045-1054 19-Click and Release: SO2 Prodrugs with Tunable Release Rates. Ji X, El-Labbad EM, Ji K, Lasheen DS, Serya RA, Abouzid KA, Wang B. Org Lett. 2017 Feb 17;19(4):818-821 20- Fragment-Based Drug Discovery in the Bromodomain and Extra-Terminal Domain Family Mostafa Radwan, Rabah Serya Arch. Pharm. Chem. Life Sci. 2017, vol. 350, eLoc. 1700147 21- Pyrazolo[1,5-a][1,3,5]triazine based scaffold as purine analogues with diverse biological activity, Mazin A. A. Najm, Rabah A. T. Serya and Khaled A. M. Abouzid Journal of American Science 2017;13(3), 76-95 http://doi:10.7537/marsjas130317.08 22-An overview on the prospective CDKs inhibitors as anti-cancer drugs: Review article, Khulood H. Oudah, Nermin S. Abdou, Rabah A. T. Serya and Khaled A. M. Abouzid, Journal of American Science 2017;13(4) 6-23 23-Novel quinoline-3-carboxamides (Part 2): Design, optimization and synthesis of quinoline based scaffold as EGFR inhibitors with potent anticancer activity Rasha M.AlyRabah A.T.SeryaAmira M.El-MotwallyAhmed EsmatSafinaz AbbasDalal A.Abou El Ella f Bioorganic ChemistryVolume 75, December 2017, Pages 368-392 13. 24-Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors Sandra N. Milik. Amal Kamal Abdel-Aziz, Deena S. Lasheen, Rabah A.T. Serya, Saverio Minucci and Khaled A.M. Abouzid, European Journal of Medicinal Chemistry 155: 316-336 (2018). IF: 4.50https://doi.org/10.1016/j.ejmech.2018.06.011 Impact Factor ISI: 4.86 25-Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: design, synthesis, biological evaluation and molecular modeling, Mai Adel, Rabah A. T. Serya, Deena S. Lasheen, Khaled A. M. Abouzid Bioorganic Chemistry, 81, 2018, 612-629. https://doi.org/10.1016/j.bioorg.2018.09.001 IF 3.9 26-Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity. Nevine M.Y. Elsayed, Dalal A. Abou El Ella, Rabah A.T. Serya, Mai F. Tolba, Marawan Ahmed, Khaled Barakat and Khaled A. M. Abouzid Bioorganic Chemistry Volume 82, February 2019, Pages 340-359 https://doi.org/10.1016/j.bioorg.2018.10.071 IF 3.9 27- Synthesis and molecular docking studies of some novel Schiff bases incorporating 6-butylquinolinedione moiety as potential topoisomerase IIβ inhibitors Hassanin, H.M., Serya, R.A.T., Abd Elmoneam, W.R., Mostafa, M.A. Royal Society Open Science 5(6),172407 2018 14. 28-Alkoxyphenylthiazoles with broad-spectrum activity against multidrug-resistant gram-positive bacterial pathogens. 15. Moustafa ElAwamy , Haroon Mohammad , Abdelrahman Hussien, Nader S. Abutaleb, Mohamed Hagras. Rabah A.T. Serya.,Azza T. Taher, Khaled AM Abouzid, Mohamed N. Seleem , and Abdelrahman S. Mayhoub European Journal of Medicinal Chemistry 152 (2018) 318e328 Impact Factor: 4.50https://doi.org/10.1016/j.ejmech.2018.04.049 29- Towards Discovery of Novel Scaffold with Potent Antiangiogenic Activity; Design, Synthesis of Pyridazine based Compounds, Impact of Hinge Interaction and Accessibility of their Bioactive Conformation on VEGFR-2 Activities Maiy Y. Jaballah, Rabah A.T. Serya, Nasser Saad, Sohair M. Khojah, Marawan Ahmed, Khaled Barakat and Khaled A. M. Abouzid accepted in Journal of enzyme inhibition and medicinal chemistry July 21th, 2019 30-Advances in the discovery of activin receptor-like kinase 5 (ALK5) inhibitors. Mansour MA, Hassan GS, Serya RAT, Jaballah MY, AbouzidKAM. Bioorg Chem. 2024 Jun;147:107332. doi: 10.1016/j.bioorg.2024.107332. Epub 2024 Apr 3 31-Novel sulfonamide-indolinone hybrids targeting mitochondrial respiration of breast cancer cells. Helmy SWA, Abdel-Aziz AK, Dokla EME, Ahmed TE, Hatem Y, Abdel Rahman EA, Sharaky M, Shahin MI, Elrazaz EZ, Serya RAT, Henary M, Ali SS, Abou El Ella DA. Eur J Med Chem. 2024 Mar 15;268:116255. doi: 10.1016/j.ejmech.2024.116255. Epub 2024 Feb 32-A Fluorescence-Based Assay to Probe Inhibitory Effect of Fructose Mimics on GLUT5 Transport in Breast Cancer Cells. Rana N, Aziz MA, Serya RAT, Lasheen DS, Samir N, Wuest F, Abouzid KAM, West FG.ACS Bio Med Chem Au. 2022 Nov 7;3(1):51-61. doi: 10.1021/acsbiomedchemau.2c00056. 33-Molecular design, synthesis and biological evaluation of novel 1,2,5-trisubstituted benzimidazole derivatives as cytotoxic agents endowed with ABCB1 inhibitory action to overcome multidrug resistance in cancer cells. Abdelhafiz AHA, Serya RAT, Lasheen DS, Wang N, Sobeh M, Wink M, Abouzid KAM. J Enzyme Inhib Med Chem. 2022 Dec;37(1):2710-2724. doi: 10.1080/14756366.2022.2127700.PMID: 36168121 Free PMC article. 34-Synthesis and in vitro antiproliferative activity of certain novel pyrazolo[3,4-b]pyridines with potential p38α MAPK-inhibitory activity. Farahat AA, Samir EM, Zaki MY, Serya RAT, Abdel-Aziz HA. Arch Pharm (Weinheim). 2022 Feb;355(2):e2100302. doi: 10.1002/ardp.202100302. Epub 2021 Nov 18.PMID: 34796536 35-Molecular design, synthesis and in vitro biological evaluation of thienopyrimidine-hydroxamic acids as chimeric kinase HDAC inhibitors: a challenging approach to combat cancer. Abdel-Atty MM, Farag NA, Serya RAT, Abouzid KAM, Mowafy S. J Enzyme Inhib Med Chem. 2021 Dec;36(1):1290-1312. doi: 10.1080/14756366.2021.1933465.PMID: 34187263 Free PMC article. 36-Discovery of potent thieno[2,3-d]pyrimidine VEGFR-2 inhibitors: Design, synthesis and enzyme inhibitory evaluation supported by molecular dynamics simulations. Elrazaz EZ, Serya RAT, Ismail NSM, Albohy A, Abou El Ella DA, AbouzidKAM. Bioorg Chem. 2021 Aug;113:105019. doi: 10.1016/j.bioorg.2021.105019. Epub 2021 May 30.PMID: 34091286 37-Penicillin binding protein 2a: An overview and a medicinal chemistry perspective. Shalaby MW, Dokla EME, Serya RAT, AbouzidKAM. Eur J Med Chem. 2020 Aug 1;199:112312. doi: 10.1016/j.ejmech.2020.112312. Epub 2020 Apr 18.PMID: 32442851 Review. 38-Design, synthesis and molecular docking of novel pyrazolo[1,5-a][1,3,5]triazine derivatives as CDK2 inhibitors. Oudah KH, Najm MAA, Samir N, Serya RAT, AbouzidKAM. Bioorg Chem. 2019 Nov;92:103239. doi: 10.1016/j.bioorg.2019.103239. Epub 2019 Sep 4.PMID: 31513938 39-Tackling microbial resistance with 4H-chromen-4-one derivatives as a novel class of penicillin binding protein 2a inhibitors. Shalaby MW, Abutaleb NS, Dokla EME, Elgammal Y, Liang HW, Serya RAT, Abdallah IA, Fishovitz J, Seleem MN, Abouzid KAM. Bioorg Med Chem. 2025 Dec 1;130:118376. doi: 10.1016/j.bmc.2025.118376. Epub 2025 Sep 3.PMID: 40914108 40- Discovery of Furopyrimidine-Pyrazole Hybrid Compounds Targeting p53-MDM2 Interaction as Anticancer Agents. Mansour MA, Hassan GS, Jaballah MY, Serya RAT, Dege N, Şahin O, Sharaky M, Zhang X, Su R, Kong D, Abouzid KAM. Arch Pharm (Weinheim). 2025 Sep;358(9):e70085. doi: 10.1002/ardp.70085.PMID: 40899411 41-Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AML. El-Deen NA, DeFilippis R, Abdel-Aziz AK, Milik SN, Patel S, Ismail MI, Khaled O, Ahmed TE, Abdelfattah AG, Ali EMH, Gaballah MY, McPhillie MJ, Abouzid KAM, Serya RAT, Henary M, Minucci S, Shah NP, Dokla EME. Arch Pharm (Weinheim). 2025 May;358(5):e70002. doi: 10.1002/ardp.70002.PMID: 40346763 42-Design and synthesis of novel Hydroxamate and non-Hydroxamate HDAC inhibitors based on Chromone and Quinazolone scaffolds. Ashraf R, Adel M, Serya RAT, Ibrahim E, Haffez H, Soror S, Abouzid KAM. Bioorg Chem. 2025 Jul 1;161:108514. doi: 10.1016/j.bioorg.2025.108514. Epub 2025 Apr 28.PMID: 40319810 43-Targeting DNA repair mechanisms: Spirobenzoxazinone and salicylamide derivatives as novel candidates for PARP-1 inhibition in cancer therapy. Kadry AA, Adel M, Abubshait SA, Yahya G, Sharaky M, Serya RAT, Abouzid KAM. Bioorg Med Chem. 2025 Jul 1;124:118173. doi: 10.1016/j.bmc.2025.118173. Epub 2025 Mar 23.PMID: 40252565 Scopus H index18 Submitted Patents 1- Small molecules targeting tyrosine kinase and anticancer agents, Khaled Abouzid, Rabah T Serya, Deena Lasheen and Marwa AbdelAziz 1503/2014, appl date: 23-9-2014 2- Small molecules targeting VEGFR tyrosine kinase as anticancer agents, Dalal Abouelella, Khaled Abouzid, Rabah T Serya, and NiveneMohamed 2107/2014 appl date: 30-12-2014 3- Pyridazine compounds as tyrosine kinase inhibitors and anticancer agents, Khaled Abouzid, Mai Yousef and Rabah T Serya 546/2017, appl date: 28-3-2017 4- Thienopyrimidine compounds as tyrosine kinase inhibitors and anticancer agents Khaled Abouzid, Eman Zaglol El-Razaz and Rabah T Serya 545/2017, appl date: 28-3-2017 5- Thieno[2,3-d]pyrimidines as EGFR/Her2 dual inhibitors for cancer therapy Khaled Abouzid, Sandra Milik, Deena Lasheen and Rabah Taha 2181/2017, appl date: 26-12-2017 6- pyrrolo[2,3-d]pyrimidines as VEGFR-2 inhibitors for cancer therapy Khaled Abouzid, Mai Adel, Deena Lasheen and Rabah Taha 2182/2017, appl date: 26-12-2017